Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2019-05-13 17:01:50
Reporting Period:
Accepted Time:
2019-05-13 17:01:50
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1563880 Trevi Therapeutics Inc. TRVI () 4
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1448914 Thomas Michael Heffernan C/o Trevi Therapeutics, Inc.
195 Church Street, 14Th Floor
New Haven CT 06510
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-05-09 3,851 $0.00 3,851 No 4 C Direct
Common Stock Acquisiton 2019-05-09 2,500 $10.00 6,351 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series C Preferred Stock Disposition 2019-05-09 34,247 $0.00 3,851 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
  1. On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.